Iovance Biotherapeutics

IOVA · NASDAQ

$14.86+$0.65 (+4.57%)TodayMarket closed ·
Prev close $14.21

Latest news

  • News

    Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

  • News

    10 Health Care Stocks With Whale Alerts In Today’s Session

  • NewsHenry Khederian

    Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?

  • NewsShivdeep Dhaliwal

    Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today

  • NewsVandana Singh

    Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars

  • Press releaseGlobe Newswire

    High-Stakes October has these Biotechs Entering Crucial Stretch

  • NewsAvi Kapoor

    Crude Oil Down 1%; US Job Openings Fall In August

  • NewsAvi Kapoor

    CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics to Present at Upcoming Conferences

  • NewsHenry Khederian

    Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?

  • NewsVandana Singh

    Why Iovance Biotherapeutics Stock Hit 52-Week High

  • NewsEvette Mitkov

    Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    Why Investors Are Watching These Healthcare Movers

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

  • Press releaseGlobe Newswire

    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

  • Press releaseGlobe Newswire

    Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

  • Press releaseGlobe Newswire

    How Advanced Drug Delivery Could Improve Existing Cancer Treatments

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics to Present at Upcoming Conference

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

  • News

    Iovance Biotherapeutics Option Alert: Fri $4 Calls Sweep (3) Near The Bid: 2008 @ $0.401 Vs 3647 OI; Earnings 5/7 After Close [Est] Ref=$4.04

  • Press releasePRNewswire

    The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

  • Press releasePRNewswire

    Advanced Cell-based Therapy Booming the Success for Healthcare Sector

  • NewsAvi Kapoor

    Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  • NewsVandana Singh

    What's Going On With Iovance Biotherapeutics Stock On Friday?

  • Press releasePRNewswire

    Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

  • News

    A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics to Present at Upcoming Conferences

  • NewsVandana Singh

    Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

  • News

    Examining the Future: Iovance Biotherapeutics's Earnings Outlook

  • Press releaseGlobe Newswire

    Biotech Valuations Rise as New Clinical Platforms Show Progress

  • NewsAvi Kapoor

    Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.